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AbsTrAC
Background: Complications after injury, such as acute 
respiratory distress syndrome (ARDS), are common 
after traumatic brain injury (TBI) and associated 
with poor clinical outcomes. The mechanisms 
driving non-neurologic organ dysfunction after TBI 
are not well understood. Tissue inhibitor of matrix 
metalloproteinase-3 (TIMP-3) is a regulator of matrix 
metalloproteinase activity, inflammation, and vascular 
permeability, and hence has plausibility as a biomarker 
for the systemic response to TBI. 
Methods: In a retrospective study of 182 patients with 
severe isolated TBI, we measured TIMP-3 in plasma 
obtained on emergency department arrival. We used non-
parametric tests and logistic regression analyses to test 
the association of TIMP-3 with the incidence of ARDS 
within 8 days of admission and in-hospital mortality. 
Results: TIMP-3 was significantly higher among subjects 
who developed ARDS compared with those who did 
not (median 2810 pg/mL vs. 2260 pg/mL, p=0.008), 
and significantly higher among subjects who died 
than among those who survived to discharge (median 
2960 pg/mL vs. 2080 pg/mL, p<0.001). In an unadjusted 
logistic regression model, for each SD increase in plasma 
TIMP-3, the odds of ARDS increased significantly, OR 
1.5 (95% CI 1.1 to 2.1). This association was only 
attenuated in multivariate models, OR 1.4 (95% CI 1.0 
to 2.0). In an unadjusted logistic regression model, for 
each SD increase in plasma TIMP-3, the odds of death 
increased significantly, OR 1.7 (95% CI 1.2 to 2.3). 
The magnitude of this association was greater in a 
multivariate model adjusted for markers of injury severity, 
OR 1.9 (95% CI 1.2 to 2.8). 
Discussion: TIMP-3 may play an important role in the 
biology of the systemic response to brain injury in 
humans. Along with clinical and demographic data, early 
measurements of plasma biomarkers such as TIMP-3 may 
help identify patients at higher risk of ARDS and death 
after severe isolated TBI.
Level of evidence III.
InTroduCTIon
Each year approximately 1.7 million people suffer a 
traumatic brain injury (TBI) in the USA, of whom 50 
000 die and greater than 800 000 are left with some 
form of permanent disability.1 Beyond the primary 
neurologic injury, two-thirds of patients with TBI 
have extracranial complications that contribute 
to their deaths, and pulmonary complications are 
common among patients with severe TBI.2–5 Acute 
respiratory distress syndrome (ARDS) is a form of 
severe, acute lung injury characterized by increased 
vascular permeability resulting in protein-rich 
edema fluid flooding the alveolar space. The devel-
opment of ARDS after TBI is associated with worse 
patient outcomes and higher healthcare costs.6–10 
Understanding the molecular pathways involved in 
the systemic response to brain injury could lead to 
targeted therapies or improvements in supportive 
care after injury. Furthermore, the discovery of a 
biomarker profile that identifies patients with TBI 
who are most likely to benefit from novel therapies 
to prevent and treat ARDS could enhance study 
design and enrollment in future intervention trials.
Biomarker studies in observational cohorts of 
patients with TBI are needed to determine the 
clinical relevance and biological mechanisms of 
vascular leak in murine models of TBI. One such 
biomarker of interest is tissue inhibitor of matrix 
metalloproteinase-3 (TIMP-3). TIMP proteins 
interact with matrix metalloproteinases (MMPs) 
to regulate the extracellular matrix composition 
and play a key role in tissue remodeling and repair 
throughout the body.11 12 TIMP-3 is an appealing 
biomarker candidate for ARDS after TBI because 
it has been demonstrated to attenuate TBI-induced 
blood–brain barrier (BBB) permeability and is also 
abundant in the lung tissue.13–16 TIMP-3 stabilizes 
the vascular endothelium and blocks the vascular 
endothelial growth factor-A (VEGF-A) signaling 
by directly binding to VEGF receptor 2.17 Impor-
tantly, in animal models, TIMP-3 has been shown 
to promote normal endothelial barrier func-
tion,14 inhibit vascular endothelial permeability 
after injury,13 18 and regulate matrix degradation in 
the airspaces.13 Moreover, there are data to suggest 
that TIMP-3 is involved in neutrophil recruitment 
and regulation of inflammation in mouse models 
of acute lung injury.19 More recently, in rodent 
models of TBI treated with mesenchymal stem cells 
(MSCs) after injury, TIMP-3 was found to be a key 
soluble factor secreted by MSCs that mediated the 
protective effects of MSCs on the BBB. High doses 
of recombinant TIMP-3, administered acutely after 
TBI, attenuated BBB compromise, reduced neuroin-
flammation, and reduced cerebral edema.18 20
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Although TIMP-3 appears to play an important role in cere-
bral edema after TBI, the association of TIMP-3 with ARDS after 
TBI has not been studied. Given murine studies demonstrating 
that TIMP-3 is a critical mediator of vascular endothelial barrier 
function in the brain and the lungs, we hypothesized that plasma 
levels of TIMP-3 may be altered and may be associated with 
ARDS and mortality after severe TBI. We tested this hypothesis 
by measuring TIMP-3 concentration in plasma obtained imme-
diately after severe isolated TBI in subjects enrolled in a prospec-
tive cohort study of severely injured trauma patients.
PATIenTs And meThods
Patients
We retrospectively studied 182 patients with isolated severe 
TBI who were enrolled in a larger, prospective, observational 
cohort study at Zuckerberg San Francisco General Hospital 
between 2005 and 2014. Adult subjects meeting the criteria for 
the highest level trauma activation are eligible for enrollment in 
the larger cohort study. All subjects included in this retrospec-
tive study required mechanical ventilation and survived at least 
6 hours from time of admission. Subjects suffered severe isolated 
TBI defined by an Abbreviated Injury Scale (AIS) Head  score ≥3 
with confirmed findings of TBI on head CT scans. Subjects were 
excluded if there were other serious injuries defined as AIS 
score ≥3 in any other body region. Plasma samples were not 
available for 30 of the 212 subjects (14%) who otherwise met 
the study inclusion criteria. Eleven healthy volunteers donated 
blood samples for TIMP-3 measurements.
sample collection and TImP-3 measurements
The method of sample collection has been described previously 
in detail.21 Briefly, a 10 mL sample of blood was drawn within 
10 minutes of arrival in the emergency department (ED). The 
median time elapsed from emergency medical services (EMS) 
dispatch to ED blood draw was 34 minutes in this cohort (IQR 
28–48 minutes). The samples were immediately centrifuged and 
the plasma was stored at −80°C. Blood samples from healthy 
volunteers were processed and stored in a similar fashion. TIMP-3 
levels were measured in duplicate using Milliplex MAP Human 
TIMP Magnetic Bead Panel 2 - Immunology Multiplex Assay 
(EMD Millipore) on the Luminex platform using a Labscan 200 
analyzer (Luminex, Austin, Texas) and Bio-Plex manager V.6.1 
software (Bio-Rad, Hercules, California). A 5-point logistic 
regression curve was used to calculate the concentration from 
the fluorescence intensity of the bead measurements. The stan-
dards ranged from 97 pg/mL to 100 000 pg/mL. During the 
3-year study period, the intra-assay reproducibility was 5% coef-
ficient of variablity and the interplate variability at the range of 
sample detection was 15%. Samples that were below the level 
of detection were assigned half the lowest detectable value for 
that analyte. The mean value of the two measurements was used 
for data analysis. Three extreme outlier values identified on the 
first round of measurements were measured a second time in 
duplicate, and the mean of the four assay results was used for 
data analysis.
data collection and outcome measures
Data were collected prospectively on patient demographics, 
mechanism of injury and severity, and subsequent hospital 
course. Patients were monitored until hospital discharge or 
death. As previously described, a rigorous two-physician ARDS 
adjudication protocol was used to identify cases according to 
the Berlin definition in the first 8 days of admission.22 23 Two 
physician investigators reviewed all chest radiographs from 
the first 8 days of admission for each patient with at least one 
PaO2 in the arterial blood to fraction of inspired oxygen ratio 
(PaO2: FiO2) of <300 and adjudicated ARDS cases by consensus. 
A monitoring board of clinicians in the hospital’s Division of 
Infectious Diseases identified patients with ventilator-associated 
pneumonia (VAP) using clinical, radiographic, and microbiologic 
data.
statistical analysis
Data are presented as mean±SD, median (IQR), or n (percentage). 
Univariate comparisons were made using Student’s t-test for 
normally distributed data and Wilcoxon rank-sum for skewed 
data. A non-parametric test for trend across ordered groups 
was used to test the association between the TIMP-3 quartile 
and the incidence of ARDS and mortality rates. In exploratory 
univariate analyses, α<0.2 was considered significant for further 
investigation with regression models. In all other analyses, 
α<0.05 was considered significant. All models were repeated 
after excluding the extreme outlier value for one subject with 
plasma TIMP-3 concentration of 19 450 pg/mL.
Multivariate logistic regression models were used to adjust 
for potential confounding and to illustrate that TIMP-3 contains 
additional predictive information compared with other markers 
of severity of injury or worse clinical outcomes (age, AIS 
Head score, arrival Glasgow Coma Scale (GCS) score, trans-
fusion of blood products, vasopressor use, and shock identi-
fied by arrival base deficit, a measurement of a decrease in the 
total concentration of blood buffer base). Multivariable logistic 
regression models were tested with appropriate model checking. 
Initial models included race, sex, age, body mass index, AIS in 
the head and chest categories, crystalloid administration, base 
deficit, vasopressor use, massive transfusion (>10 units of 
packed red blood cells in 24 hours), and transfusion or indi-
vidual blood products in the first 12 hours. These variables 
were selected a priori based on biological plausibility. Age was 
included as a dichotomous variable to satisfy linearity assump-
tions of the regression models. Individuals in the highest quartile 
of age, >60 years old, were compared with younger subjects. 
Difference of fitted beta coefficient (DFBETA) statistics were 
calculated to check for influential points. The influence of 
outliers was assessed by comparing the regression model results 
including all data with the regression models that excluded 
outliers identified by DFBETA statistics. Some covariates were 
serially eliminated using likelihood ratio testing. Multivariable 
logistic regression model fit was checked with the link test and 
Hosmer-Lemeshow test. Because TIMP-3 is not a commonly 
measured biomarker or clinically available laboratory value, it 
was scaled using the SD (2090 pg/mL) of the TIMP-3 measure-
ments from the entire cohort excluding the extreme outlier of 19 
450 pg/mL. To evaluate for possible misclassification of the 16 
subjects who underwent massive transfusion and therefore may 
have had more significant injuries beyond TBI, we performed 
a chart review. The bleeding among the subjects who required 
massive transfusion was attributable to a combination of gunshot 
wounds (GSW) to the head, associated vascular, facial, or scalp 
injuries (including lacerations and degloving), and/or large 
estimated blood loss related to coagulopathy that developed 
during craniotomy procedures. Only one subject may have had 
a more significant injury in another body region that may not 
have been captured by the AIS scoring, a GSW to the clavicle 
and shoulder. To address limitations of the retrospective data 
analysis and concerns about misclassification of patients with 
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Table 1  Demographic and clinical features of subjects with isolated severe traumatic brain injury by ARDS outcome and vital status at discharge
Patient characteristics
Without Ards
(n=132)
With Ards
(n=50) P values*
Alive
(n=111)
dead
(n=71) P values*
Age (years) 46±22 44±20 0.78 40±18 53±24 <0.001
Male sex 92 (70) 42 (84) 0.051 85 (77) 49 (69) 0.26
BMI 25 (22–29) 26 (23–28) 0.54 25 (23–29) 25 (22–28) 0.56
Blunt injury 111 (84) 44 (88) 0.51 99 (89) 56 (79) 0.056
SBP <90 mm Hg in the first 12 hours 12 (9) 4 (8) 0.82 5 (5) 11 (15) 0.011
Any vasopressor on admit day 66 (54) 32 (73) 0.031 49 (48) 49 (77) <0.001
Admit base deficit <−4 38 (29) 26 (52) 0.003 32 (29) 32 (45) 0.025
ED arrival GCS score 7 (3–10.5) 6 (3–10) 0.84 8 (4–13) 3 (3–7) <0.001
Head AIS 5 (4–5) 5 (5–5) 0.033 5 (4–5) 5 (5–5) <0.001
Head AIS score >3 110 (83) 47 (94) 0.062 87 (78) 70 (99) <0.001
Craniotomy or craniectomy 44 (33) 24 (48) 0.068 37 (33) 31 (44) 0.16
Any chest injury (AIS score >0) 17 (13) 7 (14) 0.84 11 (10) 13 (18) 0.10
VAP† 5 (3) 7 (14) 0.038 16 (14) 5 (7) 0.13
TIMP-3 (pg/mL)‡ 2260 (970–3460) 2810 (1820–4380) 0.008 2080 (950–3090) 2960 (1850–4650) <0.001
Findings presented as n (%), mean±SD, and median (IQR) as appropriate.
Statistically significant results are shown in bold.
*P values refer to unpaired t-test for age, Wilcoxon rank-sum test for all other continuous variables, and unordered χ2 tests for dichotomous predictors.
†Patients with VAP identified before ARDS or in the first 8 days for subjects who did not develop ARDS.
‡Plasma sample obtained on arrival to the ED.
AIS, Abbreviated Injury Scale or; ARDS, acute respiratory distress syndrome; BMI, body mass index; ED, emergency department; GCS, Glasgow Coma Scale; SBP, systolic blood 
pressure; TIMP-3,  tissue inhibitor ofmatrix metalloproteinase 3; VAP, ventilator-associated pneumonia.
Table 2  Plasma TIMP-3* in healthy volunteers and subjects after 
traumatic injury
Clinical phenotype TImP-3 (pg/mL)
Healthy volunteers (n=11) 290 (70–810)
Isolated traumatic brain injury* (n=182) 2350 (1230–3610)
Findings presented as mean (IQR).
*Plasma sample obtained on arrival to the emergency department.
TIMP-3, tissue inhibitor of matrix metalloproteinase 3.
more significant injuries beyond TBI, a sensitivity analysis of 
the multivariate models was performed, excluding 16 (9%) of 
182 subjects who received massive transfusion. To address the 
possible influence of at-risk time and censorship by death on 
the association between TIMP-3 and ARDS, we used regression 
models with an exposure parameter by creating a variable indi-
cating at-risk time. These models include time at risk as an offset 
variable. All analyses were performed using STATA V.13.
resuLTs
demographic and clinical features of the cohort
The median age of the subjects in this cohort with was 42 years 
(IQR 27–60 years). The distribution of race was Asian (20%), 
black (18%), Pacific Islander (1%), and white (60%), and race 
was not specified for 2% of the subjects. The cohort was 20% 
Latino. Subjects were predominantly male (74%) and most 
suffered blunt injuries (85%). Head injury in this cohort was 
severe; 157 (86%) subjects had an AIS Head score >3, 156 
(86%) had a GCS score <14 on ED arrival, and 122 (67%) had a 
GCS score ≤8 on ED arrival. Overall mortality was 39% and the 
incidence of ARDS in the first 8 days of hospitalization was 27%. 
In this cohort, mortality rates did not differ between those who 
developed ARDS and those who did not (46% vs. 36%, p=0.23). 
Race and ethnicity did not differ by ARDS or vital status at 
discharge. Compared with subjects who did not develop ARDS, 
subjects with ARDS were more likely to have shock defined by 
a base deficit of <−4 on ED arrival arterial blood gas (51% vs. 
29%, p=0.004) and to be treated with vasopressors on the day of 
admission (73% vs. 54%, p=0.003) (table 1). There was a trend 
toward more severe head injury (AIS Head score >3) among 
those who developed ARDS (94% vs. 83%, p=0.062). There 
was a trend toward a higher proportion of male subjects among 
those who developed ARDS compared with those who did not 
(84% vs. 70%, p=0.052). Compared with subjects who survived 
to discharge, subjects who died were older (mean age 53±24 vs. 
40±18, p<0.001), had lower admission GCS score (median 3 
vs. 8, p<0.001), were more likely to have a more severe head 
injury (AIS Head score >3) (99% vs. 78%, p<0.001), and were 
more likely to have shock defined by a base deficit <−4 on ED 
arrival arterial blood gas, systolic blood pressure <90 mm Hg in 
the first 12 hours after ED arrival, or treated with vasopressors 
on the day of admission (table 1).
Plasma TImP-3 measurements
The range of TIMP-3 among 11 healthy subjects was 20 pg/
mL to 3700 pg/mL, with a median of 290 pg/mL (IQR 70–810 
pg/mL). The range of TIMP-3 among 182 subjects with severe 
TBI was 5 pg/mL to 19 450 pg/mL, with a median of 2350 pg/
mL (IQR 1230–3610 pg/mL) (table 2). TIMP-3 measured on ED 
arrival was significantly higher among patients who subsequently 
developed ARDS compared with those who did not develop 
ARDS in the first 8 days of admission (median 2810 pg/mL 
vs. 2260 pg/mL, p=0.008) (table 1, figure 1). Among subjects 
who survived beyond the first week after injury, TIMP-3 on ED 
arrival was significantly higher among those who developed 
ARDS compared with those who did not (median 2540 pg/mL 
vs. 1860 pg/mL, p=0.033). The incidence of ARDS significantly 
increased across TIMP-3 quartiles (non-parametric test for trend 
across ordered groups, p=0.013) (figure 2). TIMP-3 measured 
on ED arrival was significantly higher among patients who died 
compared with those who survived to discharge (median 2960 
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Figure 1  Early plasma tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) levels are higher among subjects who developed acute respiratory 
distress syndrome (ARDS) and among subjects who died compared with those who did not. Box plots of plasma TIMP-3 levels on emergency 
department (ED) arrival by ARDS status (left) and vital status (right). P values refer to Wilcoxon rank-sum tests.
Figure 2  Higher incidence of acute respiratory distress syndrome (ARDS) and mortality rate among subjects with higher levels of plasma tissue 
inhibitor of matrix metalloproteinase-3 (TIMP-3) levels. There is a significant trend of ARDS incidence and mortality rates across increasing quartiles of 
TIMP-3. The results of non-parametric tests for trend across ordered groups are indicated by the p values. ED, emergency department.
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Table 3  Association of TIMP-3* and clinical outcomes after 
traumatic brain injury in univariate and full logistic regression models
Independent variables in model
For each sd change 
in TImP-3
or (95% CI)† P values
Ards
TIMP-3 1.5 (1.1 to 2.1) 0.006
TIMP-3, AIS Head score, age>60 years, 
male sex, crystalloid*, platelet*, pRBC*, 
plasma* transfusion, shock by arrival base 
deficit
1.4 (1.0 to 2.0) 0.036
Sensitivity analysis: multivariate model‡ 
excluding subjects requiring massive 
transfusion§
1.5 (1.0 to 2.3) 0.033
Sensitivity analysis: multivariate model‡ 
excluding subjects who developed VAP 
before ARDS
1.5 (1.0 to 2.2) 0.036
death
TIMP-3 1.7 (1.2 to 2.3) 0.002
TIMP-3, AIS Head score, age>60 years, male 
sex, crystalloid*, platelet *, blood*, plasma* 
transfusion, shock by arrival base deficit§
1.9 (1.2 to 2.8) 0.002
Sensitivity analysis: multivariate model‡ 
excluding subjects requiring massive 
transfusion
1.9 (1.2 to 3.1) 0.005
Crystalloid infusion included as a continuous variable indicating liters transfused in 
the first 12 hours of admission.
*Plasma sample obtained on arrival to the ED. 
†Regression model output for scaled predictor variable is interpreted as the change 
in the OR for outcome of interest for each SD (2090 pg/mL) increase in the plasma 
concentration of TIMP-3 on ED arrival, holding all other variables in the model 
constant. AIS, models exclude subjects with AIS Head score=6 (non-survivable 
injury). Platelet, pRBC, and plasma (fresh-frozen plasma) coded as binary variables 
indicating any transfusion of the specific products in the first 12 hours of admission. 
Crystalloid infusion included as a continuous variable indicating liters transfused in 
the first 12 hours of admission.
‡Multivariate model refers to full model with independent variables specified in 
the row above. Massive transfusion defined as requiring >10 units of pRBCs in 24 
hours. Sensitivity analyses excluded 16 (9%) of 182 patients in the full cohort who 
required massive transfusion.
§Base deficit of <−4 on ED arrival arterial blood gas analysis.
AIS,  Abbreviated Injury Scale; ARDS,  acute respiratory distress syndrome; ED,  
emergency department; pRBCs,  packed red blood cells; TIMP-3, tissue inhibitor 
of matrix metalloproteinase 3; VAP, ventilator-associated pneumonia.
Table 4  Association of TIMP-3* and clinical outcomes after 
traumatic brain injury in univariate and multivariate logistic regression 
models
Independent variables in model
For each 1000 pg/
mL increase in 
TImP-3
or (95% CI)† P values
Ards
TIMP-3 1.5 (1.1 to 2.1) 0.006
TIMP-3, shock by arrival base deficit‡ 1.4 (1.0 to 1.9) 0.031
TIMP-3, vasopressor on day of admission 1.6 (1.2 to 2.2) 0.004
TIMP-3, age>60 1.5 (1.1 to 2.1) 0.005
TIMP-3, GCS score 1.5 (1.1 to 2.1) 0.006
TIMP-3, AIS Head score 1.5 (1.1 to 2.0) 0.009
TIMP-3, platelet transfusion§ 1.5 (1.1 to 2.1) 0.006
TIMP-3, pRBC transfusion§ 1.5 (1.1 to 2.1) 0.007
TIMP-3, plasma transfusion§ 1.6 (1.1 to 2.1) 0.005
TIMP-3, AIS Head score, male sex, age>60, 
crystalloid, platelet, blood, plasma 
transfusion§, shock‡
1.4 (1.0 to 2.0) 0.036
death
TIMP-3 1.7 (1.2 to 2.3) 0.002
TIMP-3, shock by arrival base deficit‡ 1.6 (1.2 to 2.2) 0.005
TIMP-3, vasopressor on day of admission 1.7 (1.2 to 2.4) 0.002
TIMP-3, age>60 years 1.7 (1.2 to 2.3) 0.002
TIMP-3, GCS score 1.6 (1.2 to 2.3) 0.005
TIMP-3, AIS Head score 1.7 (1.2 to 2.5) 0.001
TIMP-3, platelet transfusion§ 1.7 (1.2 to 2.3) 0.002
TIMP-3, pRBC transfusion§ 1.7 (1.2 to 2.3) 0.002
TIMP-3, plasma transfusion§ 1.7 (1.3 to 2.4) 0.001
TIMP-3, AIS Head score, age>60 years, 
crystalloid,
platelet, blood, plasma transfusion§, 
shock‡
1.9 (1.2 to 2.8) 0.002
Models exclude subjects with AIS Head score=6 (non-survivable injury).
*Plasma sample obtained on arrival to the ED.
†Regression model output for scaled predictor variable is interpreted as the change 
in the OR for outcome of interest for each 1000 pg/mL increase in the plasma 
concentration of TIMP-3 on ED arrival, holding all other variables in the model 
constant.
‡Base deficit of <−4 on ED arrival arterial blood gas analysis.
§Adjusted models control for transfusion of blood products in the first 12 hours of 
admission.
AIS, Abbreviated Injury Scale; ARDS, acute respiratory distress syndrome; 
ED, emergency department; GCS, Glasgow Coma Scale score on ED arrival; 
pRBCs, packed red blood cells; TIMP-3, tissue inhibitor of matrix metalloproteinase 
3.
pg/mL vs. 2080 pg/mL, p<0.001) (table 1, figure 1). Compared 
with subjects who survived, TIMP-3 on ED arrival was signifi-
cantly higher among subjects who died after 24 hours (median 
3030 pg/mL vs. 2080 pg/mL, p=0.0005) and among subjects 
who died after 48 hours (median 3410 pg/mL vs. 2080 pg/mL, 
p=0.0007). These differences remained significant when the 
extreme outlier value of measured TIMP-3 was excluded from 
the analyses. The mortality rate significantly increased across 
TIMP-3 quartiles (non-parametric test for trend across ordered 
groups, p=0.001) (figure 2).
Logistic regression models
Analysis with regression models showed that higher concen-
trations of plasma TIMP-3 on ED arrival were significantly 
associated with ARDS after severe isolated TBI. For each SD 
increase in plasma TIMP-3 measured on ED arrival, the unad-
justed odds of ARDS increased significantly, OR 1.5 (95% CI 
1.1 to 2.1, p=0.006) (table 3). This association was only mildly 
attenuated in models adjusted for important covariates: severity 
of head injury, base deficit, male sex, crystalloid infusion, and 
early transfusion of blood products, OR 1.4 (95% CI 1.0 to 2.0, 
p=0.036) (tables 3 and 4). The magnitude of association was 
unchanged in sensitivity analyses excluding patients who received 
massive transfusion, OR 1.5 (95% CI 1.0 to 2.3, p=0.033), and 
excluding patients who developed VAP before ARDS, OR 1.5 
(95% CI 1.0 to 2.3, p=0.027) (table 3). Similarly, this associ-
ation was not attenuated after adjusting for additional covari-
ates associated with severity of illness including vasopressor use 
and GCS score on ED arrival (table 4).24–26 Furthermore, models 
that accounted for follow-up time did not substantively change 
the association between TIMP-3 and ARDS.
Analysis with regression models showed that higher concen-
trations of plasma TIMP-3 on ED arrival were significantly 
associated with death after severe isolated TBI. For each SD 
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increase in plasma TIMP-3, the unadjusted odds of death 
increased significantly, OR 1.7 (95% CI 1.2 to 2.3, p=0.002) 
(table 3). The magnitude of this association was increased in a 
multivariate model adjusted for important covariates: severity 
of head injury, age, crystalloid infusion, early transfusion of 
blood products, base deficit, and in a sensitivity analysis of the 
multivariate model excluding patients who received massive 
transfusion (table 3). The association was not attenuated in 
several bivariate models adjusting for other markers of injury 
severity, such as vasopressor use and GCS score on ED arrival 
(table 4). In an unadjusted logistic regression analysis, subjects 
with the highest quartile of TIMP-3 concentrations, greater 
than 3610 pg/mL on ED arrival, had significantly greater odds 
of death. Specifically, the OR for death was 3.1 (95% CI 1.5 to 
6.1, p=0.002) among subjects in the highest quartile of plasma 
TIMP-3 concentration compared with subjects in the lower 
three quartiles of plasma TIMP-3 concentration. Including 
TIMP-3 in the full multivariate logistic regression models with 
clinical and demographic characteristics improved the accuracy 
of predicting the outcomes of ARDS and death after TBI (area 
under the receiver operator curve (AUROC) 0.74 vs. 0.72 and 
0.83 vs. 0.79, respectively).
dIsCussIon
In this observational cohort study, we have shown for the first 
time that among patients with severe isolated TBI, plasma 
TIMP-3 levels measured on ED arrival are associated with a 
higher risk of ARDS and a higher risk of death. This association 
was not attenuated in multivariate logistic regression models 
that controlled for covariates such as severity of head injury, 
vasopressor use, shock, volume of crystalloid infused, and trans-
fusion of blood products. Importantly, higher levels of plasma 
TIMP-3 on ED arrival were associated with death occurring 
later than 24 hours and 48 hours from the time of admission. 
The association of TIMP-3 levels with outcomes at these later 
time points suggests that elevated TIMP-3 may identify early 
differences in the pathophysiologic response to injury that have 
durable effects on patient outcomes beyond identifying patients 
who are so severely injured they die shortly after presentation. 
Collectively, these findings suggest that TIMP-3 is a potentially 
important biomarker for predicting ARDS and death after severe 
TBI. The biological role, if any, of elevated TIMP-3 levels on 
arrival in the ED is unknown and requires further investigation.
Although complications after injury such as ARDS are 
common after TBI, mechanisms mediating these effects are not 
well understood. Although there is a growing body of evidence 
from animal models describing the molecular and physiologic 
mechanisms underpinning the brain–lung crosstalk after TBI, 
little is known about these mechanisms in humans.27–35 Identi-
fying biomarkers for ARDS after isolated TBI is a relatively novel 
line of investigation. Most biomarker studies in ARDS exclude 
patients with TBI or do not distinguish isolated TBI as a distinct 
clinical phenotype within the general trauma population. As in 
other at-risk populations, it is likely that multiple biological path-
ways drive the pathophysiology of ARDS after TBI.36–39 Recently, 
in a cohort study of 200 patients with severe TBI, Aisiku et al40 
found an association between ARDS and an elevation in early 
inflammatory plasma cytokines, interleukin (IL)-6 and IL-8, and 
anti-inflammatory cytokine, IL-10. Our study builds on these 
findings by testing the association of a biomarker of vascular 
stability with ARDS after TBI. The association between TIMP-3 
and worse clinical outcomes after isolated TBI supports the 
hypothesis that the vascular endothelium has an important 
biological role in the pathogenesis of complications after injury, 
such as ARDS and death.
Identifying patients at the highest risk for ARDS after TBI 
would be clinically useful. For example, those at the highest risk 
for ARDS might benefit from the implementation of early lung 
protective ventilation protocols, closer monitoring for oxygen-
ation deficits, or screening for evidence of cardiopulmonary 
volume overload with directed bedside ultrasound in the inten-
sive care unit. Given an increased interest in the prevention and 
early treatments for acute lung injury, the development of reli-
able methods for identifying patients at the highest risk of ARDS 
is an important line of future investigations.41 42
Although TIMP-3 has not been studied in ARDS, it plays an 
important role in the mouse models of postinjury brain edema, 
and its role in vascular leak and localization in the lung tissue 
supports the biological plausibility for a role in ARDS.18 20 The 
association between TIMP-3 and poor clinical outcomes after 
isolated TBI is consistent with the hypothesis that dysregulated 
MMP activity may be involved in vascular endothelial stability 
and play an important role in the pathogenesis of complications 
after injury, such as ARDS and death, in patients with TBI. It 
is notable that the direction of the association between higher 
TIMP-3 levels and worse outcomes was unexpected. Since 
TIMP-3 administration has been shown to have a therapeutic 
effect in animal models of TBI,18 20 it is interesting that in this 
clinical study we found that elevated levels of TIMP-3 after TBI 
are associated with poor outcomes. We speculate that the differ-
ences between our findings and previously published data from 
mouse models may be explained by one of three hypotheses: (1) 
increased plasma TIMP-3 could be a surrogate marker for injury 
severity through either passive release of TIMP-3 from injured 
tissue or from an active homeostatic mechanisms to maintain 
the MMP:TIMP balance; (2) increased plasma levels of TIMP-3 
may represent movement of endogenous and beneficial TIMP-3 
activity into the systemic vascular compartment, away from the 
injured brain and lung tissue, impeding recovery from injury in 
these organs; and (3) the plasma levels of TIMP-3 in the patients 
are far lower than the therapeutic range tested in mice. The 
levels of TIMP-3 found in the plasma of injured patients (median 
of 2350 pg/mL) are 400-fold lower than the amount used for 
therapeutic purposes in preclinical models.18 20 It is also possible 
that TIMP-3 biology is fundamentally different between humans 
and mice.
Our study has some limitations. This is a retrospective, single-
center study and may have limited generalizability. Larger 
follow-up studies would be needed to validate the use of TIMP-3 
as a biomarker for ARDS and mortality after TBI. Although 
the AIS and GCS are widely used in trauma research, AIS Head 
and GCS scores do not capture much information about the 
nature of brain injury in these subjects and do not account for 
location or volume of injury; therefore, our adjusted analyses 
may not fully capture the effect of severity of head injury on 
ARDS or mortality outcomes. Because we studied patients with 
severe brain injuries that required intubation, our findings may 
not be generalizable to patients with less severe injuries and 
higher GCS scores. Furthermore, using AIS classifications to 
define isolated TBI has limitations. To address possible misclas-
sification of subjects who underwent massive transfusion and 
therefore may have had more significant injuries beyond TBI, 
we performed chart review and sensitivity analyses excluding 
these subjects (table 3). This study did not measure TIMP-3 
activity, and it is unclear if we are measuring displaced and inac-
tive protein from tissue disruption or active protein released 
from tissue stores or platelet degranulation. Because the protein 
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is measured immediately on arrival to the ED, the short time 
interval between injury and sampling makes it less likely that 
we are measuring newly synthesized protein. We are not able 
to comment on the origin of circulating TIMP-3 protein in 
the plasma. We also acknowledge that the range of TIMP-3 in 
this study has significant overlap between subjects who devel-
oped ARDS and those who did not, as well as subjects who 
survived and those who died. However the biological plausibility 
for the role of MMPs in the pathogenesis of complications after 
injury and the robust association between TIMP-3 and clinical 
outcomes in adjusted multivariate models support the hypothesis 
that TIMP-3 may be useful as one of a panel of biomarkers that 
could improve clinical prediction models of poor outcomes after 
TBI. Furthermore, we found that the incidence of ARDS and 
mortality rates significantly increased across TIMP-3 quartiles, 
suggesting that there may be a threshold above which plasma 
TIMP-3 levels may be particularly informative in clinical studies 
of postinjury complications after TBI. Further studies are needed 
to better understand the role of TIMP-3 in the biological path-
ways involved in the response to brain injury.
Our study has several strengths. Our cohort is designed for 
early plasma sample collection, allowing us to capture informa-
tion on patients before confounding interventions and before the 
development of ARDS. The differences in plasma TIMP-3 levels 
occurred soon after injury, and measurements were unlikely to 
be altered by administration of fluids or blood products. The 
median time from EMS dispatch to ED blood draw was 34 
minutes, and only 15 (8%) subjects received more than 500 mL 
of crystalloids prior to ED arrival. We use a rigorous adjudi-
cation protocol for ARDS, minimizing misclassification bias.23 
Our adjusted models accounted for several measures of severity 
of injury. The association between TIMP-3 levels and clinical 
outcomes was not attenuated by measures of severity of brain 
injury or shock on arrival to the ED. In a multivariate model that 
includes clinical predictors strongly associated with the outcome, 
the degree of change we observed in the AUROC tests suggests 
that, although TIMP-3 alone is inadequate for the prediction of 
ARDS and death after TBI, it meaningfully improves the ability 
of the model to predict ARDS and death after TBI in this cohort.
ConCLusIon
Our study is one of the few studies to test the association of a 
plasma biomarker and ARDS after isolated TBI. Our findings 
suggest TIMP-3 may play an important role in the biology of 
the systemic response to brain injury in humans. Specifically, the 
findings support the hypothesis that early endothelial injury and 
vascular permeability may be important in the pathogenesis of 
ARDS after TBI. Furthermore, early plasma TIMP-3 levels, in 
combination with clinical information and other biomarkers, 
could be useful in future studies to identify patients at highest 
risk of ARDS and death after isolated TBI.
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